Merck Provides New Funding to Fight HIV/AIDS in Botswana
- Details
- Category: Merck
Merck announced the Merck Company Foundation and the Bill & Melinda Gates Foundation are committing an additional $60 million to support Botswana's African Comprehensive HIV/AIDS Partnerships (ACHAP). Merck is known as MSD outside the US and Canada.
World Health Organization Grants Prequalification to Prevenar 13
- Details
- Category: Pfizer
The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the vaccine.
GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the prevention of shingles. The phase III clinical trials will study more than 30,000 patients globally and will evaluate the efficacy, safety and immunogenicity of the candidate vaccine.
Roche acquires BioImagene, a leading provider of digital pathology laboratory solutions
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed an agreement under which Ventana Medical Systems Inc., a member of the Roche Group, will acquire 100 percent of BioImagene, Inc., a privately held company based in Sunnyvale, California.
GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta®
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE).
Ipilimumab Receives FDA Priority Review Designation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated.
Lilly Halts Development of Semagacestat for Alzheimer's Disease
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.
More Pharma News ...
- Lundbeck reports strongly increasing profits with EBIT growth of 30%
- Abbott Launches New Psoriasisanswers.com Web site
- Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial
- Pfizer Reports Second-Quarter 2010 Results
- Image of new antibiotic in action opens up new opportunities
- TEMPO study further demonstrates the benefits of Azilect® in early Parkinson's disease patients
- Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen